key: cord-0939539-wtnol2tl
authors: Herman, P; Vincent, C; Parietti Winkler, C; Loundon, N; Couloigner, V; Tankere, F; Tringali, S; Gallet, P; Papon, J F; Montava, M; Lavieille, J P; Charpiot, A; Schmerber, S
title: Corticosteroid therapy in ENT in the context of the COVID-19 pandemic
date: 2020-05-04
journal: European annals of otorhinolaryngology, head and neck diseases
DOI: 10.1016/j.anorl.2020.04.014
sha: cb9bf4f1d991ba4633bef250382f186ab2ce15b2
doc_id: 939539
cord_uid: wtnol2tl

ABSTRACT This consensus statement about the indications and modalities of corticosteroid treatment in the context of the COVID-19 pandemic was jointly written by experts from the French Association of Otology and Oto-Neurology (AFON) and from the French Society of Otorhinolaryngology, Head and Neck Surgery (SFORL). There is currently not enough data in favour of danger or benefit from corticosteroids in COVID-19, so until this matter is resolved it is advisable to limit their indications to the most serious clinical pictures for which it is well established that this type of treatment has a positive impact on the progression of symptoms. In Grade V and VI Bell's palsy according to the House-Brackmann grading system, a week’s course of oral corticosteroids is recommended. Corticosteroid therapy is also recommended in cases of sudden hearing loss of more than 60 dB, either in the form of intratympanic injections or a week’s course of oral medication. In rhinology, there is no indication for systemic corticosteroid therapy in the current situation. However, patients are advised to continue with their local corticosteroid therapy in the form of a nasal spray or by inhalation. Treatments with corticosteroid nasal sprays can still be prescribed if there is no alternative.

The COVID 19 pandemic has a high mortality rate for which the identified risk factors are obesity, older age (>65 years), the male sex, high blood pressure, a history of stroke, coronary heart disease, heart failure, uncontrolled diabetes, chronic respiratory illnesses, renal failure treated by dialysis, and progressive cancer (http://www.ebola.sante.gouv.fr/soins-et-maladies/prises-en-chargespecialisees/obesite/article/obesite-et-covid-19; https://www.hcsp.fr/explore.cgi/avisrapports).

Although not formally established, cirrhosis and a history of splenectomy (or homozygous sickle cell anaemia) may also be factors (https://www.hcsp.fr/explore.cgi/avisrapports).

There is currently no scientific data to suggest a particular benefit or risk from corticosteroids in COVID- J o u r n a l P r e -p r o o f 5 malades-traites-par-immunosuppresseurs-ou-biotherapies). In the absence of scientific publications concerning the possible risks of corticosteroid therapy during the COVID-19 pandemic, AFON and SFORL plan to restrict its indications to ENT pathologies for which efficacy is best established. In cases of Bell's palsy, the efficacy of corticosteroids is well established [2] . In the current pandemic situation, the therapeutic indication should be adapted to the severity of the symptoms. In incomplete forms, it is not advisable to commence treatment with drugs. Only eye care should be prescribed. In severe forms (grades V-VI according to the House-Brackmann grading system) and in the absence of any of the symptoms associated with COVID-19 (fever, cough, headaches, myalgia, anosmia

(2) the test available at the present time, RT-PCR on a nasopharyngeal swab, has limited reliability (40% false negatives) [3] , and (3) since facial paralysis is not part of the consensus indications for these RT-PCR, sampling centres will usually refuse to do them. The indications for diagnostic tests prior to treatment are likely to change over the course of the next few weeks or months as and when new more effective diagnostic tests arrive, in particular serological ones. An oral antiviral treatment (Valaciclovir 3 grams/day) could also be prescribed in cases of shingles [4] . Oral corticosteroid therapy can usually be administered at home under the supervision of a general practitioner. Admission to hospital should be discussed in cases of unstable insulin-dependent diabetes, unstable heart disease undergoing treatment, eye disease, miscellaneous other comorbidities or old age. In subsequent treatment, ophthalmological monitoring should be set up and an ENT teleconsultation scheduled one month after corticosteroid therapy, ideally in the form of a remote consultation. In cases of facial paralysis combined with symptoms of COVID-19, the diagnostic tests to be performed and setting up of corticosteroid therapy if applicable should be discussed locally on a case-by-case basis with the team responsible for diagnosing and caring for COVIDpositive patients.

As far as possible, determining the hearing threshold and type of audiometric curve should be achieved by remote consultation in line with the methods stipulated in the best practice recommendations compiled under the aegis of the French Society of Audiology (SFA) and of SFORL [5] . In cases of suspected hearing loss of more than 60 dB, a face-to-face consultation with a hearing test is desirable.

7

As concerns treatment, the advantage of using corticosteroids is well proven, as is the likely superiority of intratympanic injections (ITI) compared to systemic administration [6] . In the current situation, the indications for this type of treatment should be limited to severe forms with unilateral hearing loss of more than 60 dB, especially in cases of a single functioning ear, and in the absence of any clinical symptoms of COVID-19. We recommend proposing transtympanic corticosteroid injections rather than systemic treatment. Wherever possible, in order to reduce the risks of contaminating patients with SARS-CoV-2, this treatment should be conducted in an ENT clinic rather than in hospital. As in cases of facial paralysis and for the same reasons, admission to hospital should be discussed in cases of unstable insulin-dependent diabetes, unstable heart disease undergoing treatment, eye disease, miscellaneous other comorbidities or old age. Routinely carrying out RT-PCR tests on nasopharyngeal swabs before starting corticosteroid therapy is not recommended. The progression of the hearing loss should ideally be monitored by remote consultation [5] . A scan or other necessary examination should be prescribed in order to assess the cause. In cases of sudden hearing loss combined with symptoms of COVID-19, the diagnostic tests to be performed and setting up of corticosteroid therapy if applicable should be discussed locally on a case-by-case basis with the team responsible for diagnosing and caring for COVID-positive patients.

Symptomatic or etiopathogenic treatment is delivered after teleconsultation (betahistine, acetazolamide, acetylleucine). Intratympanic corticosteroid injections, which are sometimes useful for this indication [7- 

Conseils de bonne pratique sur la consultation en ORL en contexte de pandémie de Covid-19. Eur Ann Otorhinolaryngol Head Neck Dis

Corticosteroids for Bell's palsy (idiopathic facial paralysis)

COVID-19) in China: A Report of 1014 Cases. Radiology

Antiviral treatment for Bell's palsy (idiopathic facial paralysis)

La téléconsultation médicale en Audiologie. Conseils de bonnes pratiques de la Société Française d'Audiologie (SFA) et de la Société Française d'ORL et de Chirurgie Cervico-Faciale (SFORL)

A comparison between systemic and intratympanic steroid therapies as initial therapy for idiopathic sudden sensorineural hearing loss: a meta-analysis

Intratympanic dexamethasone, intratympanic gentamicin, and endolymphatic sac surgery for intractable vertigo in Meniere's disease

Transtympanic perfusion: indications and limitations

Intratympanic corticosteroids in Ménière's disease: A mini-review

International consensus (ICON) on treatment of Ménière's disease

Eur Ann Otorhinolaryngol Head Neck Dis

Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

Smell and taste dysfunction in patients with COVID-19

SARS-CoV-2: Olfaction, Brain Infection, and the Urgent Need for Clinical Samples Allowing Earlier Virus Detection

Olfactory Loss Function as a Possible Symptom of COVID-19